DRAGEN CGIS integrates Edico Genome’s Complete Suite of Somatic, Germline, Joint Genotyping and RNA Gene Fusion pipelines with upstream and downstream partnerships, including with Fabric Genomics, to offer a complete out-of-the-box, go-to-market solution for developing sequencing-based LDTs. DRAGEN CGIS encompasses sample accessioning, lab tracking, secondary analysis of next-generation sequencing (NGS) data, tertiary analysis of NGS data, electronic medical record (EMR) integration, test kit offerings and an implementation starters toolkit.
“The adoption of next-generation sequencing is transforming patients’ lives by enabling individualized care, and should not be limited to laboratories based on their size or budgets,” said Pieter van Rooyen, Ph.D., president and chief executive officer at Edico Genome. “To ensure that as many patients as possible benefit from the clinical uses of next-generation sequencing, as an industry we must work to provide labs with the tools they need to ease the development of personalized tests. Through our DRAGEN Complete Suite and partnerships with other industry leaders, we believe our end-to-end CGIS solution sets a new industry standard for not only speed and accuracy, but also simplicity and ease of use.”
Last month, Edico Genome and Fabric Genomics announced their integrated solution for secondary and tertiary analysis for whole genome sequencing data, with a successful implementation at Rady Children’s Institute for Genomic Medicine. Fabric Genomics’ newly expanded somatic cancer interpretation capabilities for solid tumors, hematology, and liquid biopsy samples will now be integrated into DRAGEN CGIS. The somatic cancer offering includes variant calling, annotation from cancer-specific databases, clinical curation from multiple providers, and the ability to quickly create physician-ready clinical reports. Fabric Genomics’ somatic solution complies with the AMP guidelines, which includes a tier-based reporting system, with levels of evidence for each variant’s ability to predict response or resistance to a therapy.
“The clinical genomics market is fragmented and there is a need for standardization and integration to overcome cumbersome workflows,” said Martin Reese, Ph.D., co-founder and chief executive officer at Fabric Genomics. “Fabric Genomics is working closely with leading technology partners such as Edico Genome to enable quick implementation of NGS analysis pipelines to clinical labs. By combining Fabric Genomics’ interpretation platform with DRAGEN’s variant calling offering, we enable laboratories to quickly interpret and report on genomic insights to guide patient care for hereditary diseases and cancer – a critical gap to overcome for wider genomic adoption in healthcare.”
DRAGEN CGIS is the first generation of Edico Genome’s holistic end-to-end solution. The company will continue to expand and integrate additional pipeline and partnership offerings to deliver even greater functionality and utility.
“Our goal is to remove the bottlenecks preventing labs from deploying sequencing-based tests by providing an end-to-end solution that dramatically accelerates time to market, and DRAGEN CGIS is the first step to making this a reality,” added Dr. van Rooyen. “We look forward to bringing new offerings and options to our customers as part of our comprehensive solution, and welcome partners to join us on this endeavor.”
To learn about DRAGEN CGIS and Edico Genome’s Complete Suite of Germline, Somatic and RNA analysis solutions, including the integrated workflow with Fabric Genomics, visit Edico Genome’s booth #1802 and Fabric Genomics’ booth #827 at AMP.